Digital Health: Optimizing Clinical Trials with Patient-Centric Technology

Digital health is the use of digital platforms, such as mobile phones and wearable devices, to bring healthcare directly to the patient and provide medical treatment that focuses on the personalized needs of the individual. This personalized approach to healthcare is particularly important for the optimization of clinical trials in psychiatry.

Psychiatric populations are highly heterogeneous, both in terms of symptom severity and cognitive ability. Therefore, when testing a new compound designed to alleviate psychiatric symptoms or exert pro-cognitive effects, it is vitally important to consider the individual variability of the clinical population. In the past, these considerations have often not been accounted for and drug efficacy may have gone undetected as a result.

In this webinar, Director of Digital Neuroscience at Cambridge Cognition, Dr Nathan Cashdollar, and Senior Director of Product Innovation at ICON PLC, Marie McCarthy, will navigate you through the new field of digital health in psychiatry, to conclude which technologies look to be most promising for optimizing clinical trials, and how to successfully operationalize these digital solutions.

Speakers

Nathan Cashdollar, PhD, Director of Digital Neuroscience, Cambridge Cognition

With over a decade of experience in both academic and clinical research, Nathan is an expert in the development of scientifically valid and clinically sensitive digital solutions for measuring cognitive performance in healthcare and clinical trial research environments. In his current role at Cambridge Cognition, Nathan provides comprehensive scientific consultancy and potentiates the development of digital innovations for clinical trial experimentation in order to optimize outcomes.

Message Presenter

Marie McCarthy, MBA, Senior Director of Product Innovation, ICON PLC

Within the multidisciplinary Innovation Team at ICON PLC, Marie is responsible for developing solutions in the direct-to-patient paradigm. Here the primary focus is on the use of wearables and sensors to collect clinically sensitive endpoints in non-clinical settings, such as the patient home. In her previous role at Philips Respironics, Marie built awareness of the value of Actigraphy endpoints as objective measures of clinical change among clinicians and researchers.

Message Presenter